Filtered By:
Drug: Taxotere

This page shows you your search results in order of date. This is page number 8.

Order by Relevance | Date

Total 2208 results found since Jan 2013.

Retrospective study of treatment patterns and natural history of patients with T1a/b N0 TNBCs-A single-institution experience
CONCLUSIONS: In our cohort, all patients with T1a/b node- TNBCs were treated with adjuvant chemotherapy and had favorable outcomes even when treated with anthracycline-sparing regimens.PMID:37527637 | DOI:10.1159/000533149
Source: Oncology - August 1, 2023 Category: Cancer & Oncology Authors: Langfeier Liu Nicholas Lewis Weihong Sun Junmin Whiting Susan Hoover Ricardo L B Costa Source Type: research

The STAMPEDE2 Trial: a Site Survey of Current Patterns of Care, Access  to Imaging and Treatment of Metastatic Prostate Cancer
CONCLUSION: There is noteworthy disparity in clinical practice across current study sites, however most have expressed an interest in participation in the forthcoming STAMPEDE2 trial.PMID:37507278 | DOI:10.1016/j.clon.2023.07.009
Source: Clinical Prostate Cancer - July 28, 2023 Category: Cancer & Oncology Authors: H Abdel-Aty L O'Shea C Amos L C Brown E Grist G Attard N Clarke W Cross C Parker M Parmar N Vas As N James Source Type: research

Predictors of outcomes of docetaxel treatment in de novo metastatic hormone-sensitive prostate cancer: A single-center cohort study
We report a cohort of 73 consecutive patients with de novo mHSPC treated with early docetaxel at the Department of Oncology and Radiotherapy, University Hospital of Split, Croatia, from October 2015 until March 2020. The outcomes analyzed were the occurrence of castration-resistant disease (CRPC) and death from any cause (OS). The median follow-up was 54 (50-73) months. Forty-six (63%) patients developed CRPC and 34 (47%) died during the follow-up. The median time to CRPC and median OS were 16.2 and 58.4 months, respectively. The risk of CRPC was higher for patients with high (above median) values of serum alkaline phospha...
Source: Neoplasma - July 27, 2023 Category: Cancer & Oncology Authors: Tomislav Omr čen Davor Eterovi ć Tea Jozi ć Eduard Vrdoljak Source Type: research